PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis

Several drugs approved for a variety of indications have been shown to exhibit antiangiogenic effects. Our study focuses on the PPARγ ligand rosiglitazone, a compound widely used in the treatment of type 2 diabetes. We demonstrate, for the first time to our knowledge, that PPARγ is highly expressed...

Volledige beschrijving

Bewaard in:

Bibliografische gegevens
Gepubliceerd in:	J Clin Invest
Hoofdauteurs:	Panigrahy, Dipak, Singer, Samuel, Shen, Lucy Q., Butterfield, Catherine E., Freedman, Deborah A., Chen, Emy J., Moses, Marsha A., Kilroy, Susan, Duensing, Stefan, Fletcher, Christopher, Fletcher, Jonathan A., Hlatky, Lynn, Hahnfeldt, Philip, Folkman, Judah, Kaipainen, Arja
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	American Society for Clinical Investigation 2002
Onderwerpen:	Article
Online toegang:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC151148/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/12370270/ https://ncbi.nlm.nih.govhttps://doi.org/10.1172/JCI15634
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!

PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis

Gelijkaardige items